Analystreport

Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) had its price target lowered by analysts at Citigroup Inc. from $4.00 to $3.00. They now have a "buy" rating on the stock.

Eiger BioPharmaceuticals, Inc.  (EIGR) 
Last eiger biopharmaceuticals, inc. earnings: 3/13 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.eigerbio.com